Introduction: Somatostatin analogues (SSA) are indicated in the control of secretory symptoms of digestive endocrine tumors. The antiproliferative effect of SSA was recently demonstrated (Rinke et al, JCO 2009).
Aim(s): To identify factors associated with tumor control in a group of patients with WDEC treated with lanreotide.
Materials and methods: Retrospective study in 68 patients with WDEC treated with lanreotide alone, primary endpoint: PFS. Uni- and multivariate analysis on age, gender, discovery mode, origin of the primary tumor, metastatic spread, Ki-67 index, grade of uptake on SRS, pre-treatment evolutivity, extent of liver involvement, resection of the primary, and tumor markers.
Conference: 8th Annual ENETS Conference (2011)
Presenting Author: Pr Philippe Ruszniewski
To read results and conclusion, please login ...
Further abstracts you may be interested in